Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Organon

1923 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of drugs for the treatment of schizophrenia in adults. The company provides drugs for the treatment of schizophrenia in adults, and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, as monotherapy or as adjunctive therapy with either lithium or valproate.

Website
Formerly Known As
Zwanenberg-Organon
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Drug Discovery
Other Healthcare Services
Parent Company
Primary Office
  • Oss
  • Netherlands

Organon Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Organon‘s full profile, request access.

Request full access to PitchBook

Organon Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Organon‘s full profile, request access.

Request full access to PitchBook